Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)

• Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Vol. 109; no. 5; p. 20
• Main Authors: Neznamov, G G, Siuniakov, S A, Teleshova, S E, Chumakov, D V, Reutova, M A, Siuniakov, T S, Mametova, L E, Dorofeeva, O A, Grishin, S A
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 2009
• Subjects: Adamantane - administration & dosage; Adamantane - analogs & derivatives; Adamantane - therapeutic use; Anti-Anxiety Agents - administration & dosage; Anti-Anxiety Agents - therapeutic use; Central Nervous System Stimulants - administration & dosage; Central Nervous System Stimulants - therapeutic use; Humans; Neurasthenia - diagnosis; Neurasthenia - drug therapy; Placebos; Time Factors; Treatment Outcome

An aim of a randomized blind study was to assess therapeutic efficacy and safety of ladasten used as an antiastenic drug in patients with neurasthenia. Tasks of the study included the investigation of characteristics of therapeutical actions, efficacy of the drug comparing to placebo, possible side-...